The content on this site is intended for healthcare professionals only
Dr Jahn talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about the development of a platform for the rapid identification of high affinity T cell receptors (TCRs) of therapeutic relevance targeted to self-antigens.
This is done by combining gene expression data with valuable information on peptide processing from peptide elution studies and exploiting the immunogenicity of foreign human leukocyte antigen (HLA).
Using this platform the team successfully isolated CD20-specific TCRs which could broaden the application of immunotherapies targeted to CD20 in cases where CD20-cell surface expression is low.
Based on its general principle the developed platform could easily be adapted to target other malignancies.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Choosing 1st line TKI Wisely in patients with CML
Multiple myeloma In Rwanda: The need for further research
